Neurorescue and DHA on a 6OHDA preclinical Parkinson model

Neurorescue and DHA on a 6OHDA preclinical Parkinson model

25 Jan Neurorescue and DHA on a 6OHDA preclinical Parkinson model

Preclinical data collected in models of preclinical Parkinson disease (PD) support the neuroprotective potential of omega-3 polyunsaturated fatty acids (n-3 PUFA)-enriched diet on the dopaminergic (DAergic) system. In this study, we investigated the effects of a n-3 PUFA rich diet using a neurorescue/neurorestorative paradigm. C57BL/6 adult mice were submitted to a striatal stereotaxic injection of the neurotoxin 6-hydroxydopamine (6-OHDA) to induce DAergic denervation and subsequent nigral DAergic cell loss. Three weeks post-lesion, mice received either a docosahexaenoic acid (DHA)-enriched or a control diet for a period of 6 weeks. HPLC analyses revealed a 52 % post-lesion increase in striatal dopamine levels in the DHA-fed animals compared to controls (ctrl, P<0.05), although no improvement in the motor behavior was observed. DHA treatment led to a 47 % rise in tyrosine-hydroxylase (TH) - immunoreactive terminals within the striatum (P<0.05) in lesioned animals. Despite the fact that DHA did not change the number of TH+ neurons in the substantia nigra pars compacta (SNpc), morphological analyses revealed an increased in perimeters (+6%) and areas (+17) of DAergic cell bodies in treated animals. Collectively, our results suggest that DHA induce a partial neurorescue/neurorestoration of the DAergic system and support further studies to investigate the potential of a diet-based intervention, or at least the combination of such approach, to current treatments in PD.About the article: http://dx.doi.org/10.1016/j.jnutbio.2015.11.014About Syncrosome: Syncrosome is a scientific preclinical CRO based in France focused on validating animal disease models to assess the efficacy of new compounds in the field of CNS, Cardiovascular, Gastrointestinal and Respiratory diseases.

No Comments

Post A Comment